Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation | |
---|---|---|
D003141 | Communicable Diseases NIH | 0.08 |
D007239 | Infection NIH | 0.05 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
the purpose of this study: to evaluate the safety, tolerability and immunogenicity of the drug "Gam-COVID-Vac Lyo", a lyofilizate for preparing solution for intramuscular administration, at various times after vaccination in healthy adult volunteers.
Description: Determination of antibody levels against the SARS-CoV-2 glycoprotein S measured by an ELISA vs. baseline values
Measure: The changing of antibody levels against the SARS-CoV-2 glycoprotein S at 42 days Time: at days 0, 14, 21, 28, 42Description: Determination of Number of Participants With Adverse Events
Measure: Number of Participants With Adverse Events Time: through the whole study, an average of 180 daysDescription: Determination of virus neutralizing antibody titer
Measure: The changing of virus neutralizing antibody titer Time: at days 0, 14, 28, 42Description: Determination of antigen-specific cellular immunity (specific T-cell immunity, in particular, IFN-gamma production or lymphoproliferation)
Measure: The changing of antigen-specific cellular immunity level Time: at days 0, 14, 28